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Summary.-The cytotoxicity of hexamethylmelamine (HMM) and its metabolites
pentamethylmelamine (PMM), N,2,2,4,6-tetramethylmelamine (TMM) and hydroxy-
methylpentamethylmelamine (HMPMM) and of the alkylating agent triethylene-
melamine (TEM) were studied on a cell line derived from a human ovarian cancer,
by measuring [3H]TdR uptake.
After 24 h of incubation all the tested compounds inhibited [3H]TdR uptake, but
only at a concentration of 100 ,ug/ml. However, after 120 h incubation, concentrations
of 0-1-10 ,g/ml resulted in highly significant cytotoxicity. HMPMM and TEM were
the most active and their effect was not reversed 72 h after their removal. In our in
vitro system no metabolism of HMM was observed.
HEXAMETHYLMELAMINE (HMM) is an
anticancer drug which in Phase II trials
has shown consistent activity in several
human malignancies (Blum et al., 1973;
Legha et al., 1976); its effectiveness has
been demonstrated in ovarian cancer
(Wilson et al., 1969) and oat-cell carcinoma
of the lung (Takita & Didolkar, 1974).
The mechanism of action of HMM is
unknown and, despite its structural simi-
larity to triethylenemelamine (TEM) it
does not appear to act as an alkylating
agent (Worzalla et al., 1973). For this
reason it can be used in combination
therapy or in patients who have become
resistant to these drugs (Johnson et al.,
1978; Bonomi et al., 1979; Bolis et al.,
1979). HMM is extensively metabolized in
vivo through successive N-demethylation
(Bryan et al., 1968; Worzalla et al., 1974)
during which intermediate methylols are
purportedly formed (De Milo & Borkovec,
1968). An early short communication by
Heere & Donelly (1971) showed that HMM
inhibited nucleic acid synthesis much
more than protein synthesis in Ehrlich
ascites cells. More recent in vitro studies
by Rutty & Connors (1977) and Rutty &
Harrap (1978) have established that
neither HMM nor its metabolites penta-
methylmelamine (PMM) and tetramethyl-
melamine (TMM) display any cytotoxic
activity on TLX/5 cells exposed for 2 h to
1000 Htg/ml, whereas at the same concen-
trations and conditions the monomethylol
ofHMM(HMPMM) was very active. These
findings are, however, open to some
debate, since TLX/5 cells are not the most
suitable model for studying the mechanism
of action of HMM because of their lack of
response to the drug in vivo. It should be
added that the concentrations used were
about 1000 times those attainable in
animal or human plasma after drug
administration (Rutty et al., 1978;
D'Incalci et al., 1978, 1979a) and the con-
tact time of 2 h was too short, considering
that in animal tumours or cancer patients
only prolonged treatment has measurable
anticancer activity (Legha et al., 1974).
In the light of these considerations we
decided to investigate the in vitro activity
of HMM and its metabolites at different
concentrations and times of exposure,
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using a cell line derived from a human
ovarian cancer.
MATERIALS AND METHODS
The cell line E, originally derived from a
human ovarian carcinoma, was grown in a
Corning 25cm2 tissue culture flask in MEM
(Gibco BIO-CULT, Glasgow, Scotland) sup-
plemented with 10% foetal calf serum and
2mM glutamine, buffered with 20mM Hepes
(N-2-hydroxyethylpiperazine-N'-2 ethane sul-
phonic acid) (Sigma Chemical Company, St
Louis, U.S.A.).
For our experiments the cells were de-
tached from the plastic surface with a solution
containing 0 25% trypsin and 0.02% EDTA
(Gibco) in phosphate-buffered saline (PBS)
free ofCa2+ and Mg2+, for 2 min at 37°C and
suspended in fresh medium in Tissue Culture
Cluster (Costar). The inoculum was 5 x 104
cells/ml or 5x 103 in experiments of longer
duration. After 48h incubation the culture
medium was replaced with a medium con-
taining different concentrations of the test
compounds.
HMM, PMM, TMM, and TEM were sup-
plied by Dr H. Wood, NCI, Bethesda, U.S.A.,
HMPMM byDrA. Gescher, Aston University,
Birmingham, UK; formaldehyde was pur-
chased from Carlo Erba, Milan, Italy. Com-
pounds were suspended in growth medium.
All these compounds were completely dis-
solved in growth medium except HMM, the
solubility of which at 100 Hg/ml was not
complete.
In these experiments the contact time
varied from 1 to 120 h, and the medium con-
taining the drugs was renewed every 24 h. At
the end of treatment the wells were emptied,
washed again with PBS and filled with fresh
drug-free medium for up to 72h recovery.
0.5 ,uCi [3H]TdR, sp. act., 1-9 Ci/mM
(Schwarz Mann, Orangeburg, N.Y.) was
added to the medium for the last 6 h oftreat-
ment or recovery.
Cytotoxicity was measured as a percentage
of the [3H]TdR uptake by controls.
HMM and PMM were determined in the
medium by gas-liquid chromatography with
nitrogen detection after n-hexane extraction.
This method, which has been described in
detail elsewhere (D'Incalci et al., 1979a) has a
maximum sensitivity of 10 ng/ml.
The results ofthe in vitro experiments were
analysed statistically by Dunnett's test using
a total of 10-20 samples for each time and
concentration.
RESULTS
In a preliminary experiment, incubation
of E cells with HMM, PMM and TMM for
48 h at concenltrations ranging from 0 1 to
10 tg/ml did not reduce [3H]TdR uptake
(Table I). In a subsequent experiment
(Fig. 1) HMM, PMM, TMM, HMPMM and
TABLE I.-Percentage of [3H]TdR uptake
by controls after 48h exposure to HMM,
PMM or TMM at 0a1, 1 and 10 ,ILg/ml
Dose
(tKg/ml)
Control
HMM 0.1
1
10
PMM 0.1
1
10
TMM 0.1
1
10
[3H]TdR uptake + s.e.
after 48h treatment
100+ 7-8
98 + 5-4
99+4-6
102+5-0
108 + 6-9
98+2-8
93+2-0
98+2-4
92+3-6
99+2-5
TABLE II.-Percentage [3H]TdR uptake by
controls after 120h exposure to HMM,
PMM, TMM, HMPMM and TEM and
72h recovery
Dose
(tKg/ml)
Control
HMM 0.1
1
10
100
PMM 0.1
1
10
100
TMM 0.1
1
10
100
HMPMM 0-1
1
10
100
TEM 0.1
1
10
100
[3H]TdR uptake
+ s.e. after
120h treatment
100+ 5-3
62 + 5-7*
70 + 5.7*
75 + 3-6*
51 + 2-3*
84+8-2
68+ 4-2*
72+ 4-9*
49 + 3-3*
81+7-4
122+ 15-1
81+ 5-7
57 + 3-8*
75 +3.0*
75+ 3-9*
42 + 4-1*
24 + 4-2*
100+8-6
34+ 2-9*
30 + 0.9*
23 + 2-6*
[3H]TdR uptake
+s.e. after
72h recovery
100+4-1
92+8-9
95+ 11-6
84+ 100
38 + 2.9*
121+ 11.1
122 + 14-3
115+5-3
52 + 5-9*
94+ 15-4
95+04
90+ 12-8
64 + 6-3*
70 + 3.6*
53 + 4-2*
19+ 1-5*
13+0-7*
14+ 0.8*
17+0.9*
17 + 1-6*
19+ 1.0*
* P < 0 01 Dunnett's t test.
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FIG. 1.-(A) Percentage of [3H]TdR uptake by controls after 241i exposture to HMIAI, PMIIM, TMIM,
TEM, HMPAIM at 100 ptg/ml, formaldehy(le at 15 1ug/ml and PIUM 100 ,lg/ml plus formal(dohydle
15 ,ug/ml and (B) after 72h1 recovery.
TEM concentrations of 100 ,ug/ml and
formaldehyde at about an equimolar
concentration for 24 h were active, but
HMPMM, TEM and formaldehyde in-
hibited [3H]TdR uptake significantly
more than the other compounds. Form-
aldehyde at a concentration (15 jug/ml)
equimolar to HMPMM, or formaldehyde
plus PMM appear to be more cytotoxic
than HMPMM. Shortening the exposure
time to 1 h, HMPMM and TEM again
caused highly significant reduction of
TdR uptake at 100 pg/ml, respectively
68 and 67% compared to the controls,
while HMM did not. When the concentra-
tion of the drugs was reduced to 10 jug/ml
the effect was not evident after either 24h
or 48h of incubation.
In a third experiment (Table II) the
effect of the same methylmelamines and
of TEM was studied after 120 h of incuba-
tion with the drugs, and after 72 h of
recovery in a drug-free medium. [3H]TdR
incorporation was greatly reduced at 100
jug/ml (P < 0-01) by all the drugs. How-
ever, whereas with HMM, PMM and TMM,
E cells tended to recover when the drugs
were washed out, this effect was not
evident with HMPMM and TEM. WAhen
the concentrations were reduced to 10, 1
and 01 juog/ml for all the drugs, there was
no clear dose-related activity. After 120 h
of incubation, TMM lost its activity at
10 [kg/ml and TEM and PMM became
inactive at 0 1 jug/ml; significant reduction
of [3H]TdR incorporation by HMM and
HMPMM was seen even at 0 1 jug/mnl.
When the drugs were washed out for 72 h,
no cytotoxic activity was detected for
HMM, PMM and TMM previously added
at 10 jug/ml, whereas HMPMM and TEM
were still active when previously added at
0-1 jug/ml. Judging by the effects during
the presence of the drug and after its
removal, TEM and HMPMM appear to be
the most active compounds.
ct/min
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FIG. 2.-Gas chlromatograms of me(lium ex-
tracts obtained by nitrogen-phosphoirus
selective dletection. On the left is the
clhromatogram corresponding to a me(lium
extract to which we a(lde(l I /ig/ml of
HM1I, PMAI and TMM; on the right is a
elromatogram of the medium containing
1 ,ug/ml HAIM an(l incuibated with E cells
for 24 h at 37°C. TEM was used as external
stanldar(l.
The potential metabolism of HMM by
target cells was explored by measuring
PMM in the culture medium after incuba-
tion of HMM for 24 h at the concentration
of 1 jtg/ml. No GLC peak for PMM and
HMPMM was detectable when the sensi-
tivity was 10 ng/ml (Fig. 2) and HMM did
not disappear from the system.
DISCUSSION
HMM and its metabolites PMM, TMM
and HMPMM all inhibit [3H]TdR uptake
by E cells, a line derived from a human
ovarian tumour. This effect is demon-
strable at the very high concentrations of
100 tg/ml for 24 h, or for HMM and
HMPMM at the lower concentration of
04 I g/ml for 120 h. Concentrations of
10 jug/ml for 24-48 h did not produce any
cytotoxicity in our experimental condi-
tions, whereas the 100-fold lower concen-
tration for 120 h did. It therefore appears
that the potency of these compounds con-
siderably increases with longer incubation
time. This suggests that to improve the
clinical efficacy ofHMM treatment, it may
be more important to keep constant, long-
lasting plasma concentrations than to
raise the dose.
If we consider the available pharmaco-
kinetic data in humans, we see that after
a single oral dose of 120-300 mg/m2 of
HMM the plasma peak of HMM is reached
in 0 5-4 h and ranges from 0-2 to 20 jg/ml.
The plasma level then rapidly declines,
followed by a slower phase of disappear-
ance, so that after 12 h the concentration
ofH1MM ranges from 0.02 to 1P2 ,ug/ml and
after 24 h from 0 01 to 0 3 jug/ml
(D'Incalci et al., 1978, 1 979b). On the basis
of these pharmacokinetic data we would
conclude that the concentrations of HMM
we found cytotoxic in vitro are comparable
with those present in the plasma of
patients under treatment with the drug.
Bryan et al. (1968) identified all the N-
demethylated metabolites in human
plasma, and the activity of each was
evaluated by Lake et al. (1975) who
reported that HMM, PMM, TMM had
similar potency, but the potency was pro-
gressively much lower for the other
demethylated compounds. In patients
treated with HMM, plasma levels of PMM
and TMM reflect those of HMM but are
always 2-10 times lower (D'Incalci et al.,
1979b, and unpublished data).
In our in vitro system PMM and TMM
were as cytotoxic as HMM, so it is reason-
able to assume that the N-demethylated
metabolites, or at least PMM and TMM,
play a minor role in HMM in vivo activity
because they are present at lower con-
centrations. As expected from previous
reports, HMPMM is very active on the
E-cell line too, but we do not know the
relevance of this finding; in fact even
though HMPMM was recently found to be
a major metabolite of HMM incubated
with mice microsomes in vitro (Gescher
et al., 1979) it has never been identified in
vivo. Rutty and Connors (1977) reported
an increase of formaldehyde concentra-
tions in plasma of HMM-treated mice,
which indirectly suggests that HMPMM
and other methylols are formed in vivo.
The study by Kaneko & Lepage (1978) in
ll
633634 M. D'INCALCI, E. ERBA, G. BALCONI, L. MORASCA AND S. GARATTINI
which line KLN205 from mouse tumours
was found sensitive to HMM in vivo but
not in vitro, also suggests that some
metabolites other than HMM could be
responsible for the anticancer effect. The
release of formaldehyde has been offered
to explain the mode of action of HMM,
but reportedly the formaldehyde in-
hibitor semicarbazide did not prevent
HMPMM toxicity (Rutty & Connors,
1977) though a more recent report claims
that it did reverse toxicity at a very low
HMPMM concentration (Rutty & Harrap,
1978). Our data also suggest that form-
aldehyde could be responsible for
HMPMM activity; the ability of semi-
carbazide to reverse HMPMM cytotoxicity
also in our system is currently being
investigated.
We failed to find any metabolism of
HMM by E cells, which might explain the
cytotoxicity observed in terms of activa-
tion to HMPMM. In spite of our negative
results, however, this hypothesis cannot
be excluded, as the sensitivity of our
method of detecting PMM or HMPMM
(10 ng/ml) may not be sufficient consider-
ing the relatively small number of cells in
our system.
Further study is warranted to confirm
these data on primary cultures of ovarian
cancer, where in some cases it is possible
to predict the clinical efficacy (Salmon
et al., 1978) and to establish whether
HMM and its metabolites are cytotoxic at
even lower concentrations if the contact
time is fturther prolonged.
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